Reversal of thymic stromal lymphopoietin-induced airway inflammation through inhibition of Th2 responses.

Reversal of thymic stromal lymphopoietin-induced airway inflammation through inhibition of Th2 responses.
复制标题

DOI:
10.4049/jimmunol.181.9.6557
复制
发表时间:
2008-11-01
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
通讯作者:
Ziegler SF
Ziegler SF
中科院分区:
其他
文献类型:
--
作者:
Zhou B;Headley MB;Aye T;Tocker J;Comeau MR;Ziegler SF

文献摘要

参考文献

被引文献

相似文献

肺部特异性 TSLP 表达足以导致哮喘样慢性气道炎症性疾病的发展。然而,调节疾病发展的下游途径的性质尚不清楚。在这项研究中,我们使用 IL-4 和 Stat6 缺陷小鼠来确定 TSLP 下游 Th2 型反应的作用。 IL-4 缺乏大大减少了 TSLP 引起的气道高反应性 (AHR)、气道炎症、嗜酸性粒细胞增多和杯状细胞化生,但并没有消除,而 Stat6 缺乏则消除了这些哮喘样症状。我们进一步证明,使用 TSLP 介导的气道炎症的慢性模型,通过给予已确诊疾病的小鼠,通过给予抗 IL-4Rα 单克隆抗体来阻断 IL-4 和 IL-13 反应,可以逆转哮喘样症状。总的来说,这些数据提供了对 TSLP 驱动的气道炎症通路的深入了解,并证明同时阻断 IL-4 和 IL-13 可以逆转已建立的气道疾病,表明这可能是治疗 Th2 介导的炎症性呼吸道疾病的有效方法。
Lung-specific TSLP expression is sufficient for the development of an asthma-like chronic airway inflammatory disease. However, the nature of the downstream pathways that regulate disease development are not known. In this study, we used IL-4- and Stat6-deficient mice to establish the role of Th2-type responses downstream of TSLP. IL-4 deficiency greatly reduced, but did not eliminate, TSLP induced airway hyperresponsiveness (AHR), airway inflammation, eosinophilia and goblet cell metaplasia, while Stat6 deficiency eliminated these asthma-like symptoms. We further demonstrate, using the chronic model of TSLP-mediated airway inflammation, that blockade of both IL-4 and IL-13 responses, through administration of an anti-IL-4Rα monoclonal antibody, reversed asthma-like symptoms, when given to mice with established disease. Collectively these data provide insight into the pathways engaged in TSLP driven airway inflammation and demonstrate that simultaneous blockade of IL-4 and IL-13 can reverse established airway disease, suggesting that this may be an effective approach for the therapy of Th2-mediated inflammatory respiratory disease.
DOI: 10.1084/jem.20062211
发表时间: 2007-02-19
期刊: The Journal of experimental medicine
影响因子: --
作者:
Allakhverdi Z;Comeau MR;Jessup HK;Yoon BR;Brewer A;Chartier S;Paquette N;Ziegler SF;Sarfati M;Delespesse G
通讯作者: Delespesse G
DOI: 10.1172/jci200213696
发表时间: 2002-01-01
影响因子: 15.9
作者:
Temann, UA;Ray, P;Flavell, RA
通讯作者: Flavell, RA
DOI: 10.1073/pnas.0507385102
发表时间: 2005-10-11
影响因子: 11.1
作者:
Li, M;Messaddeq, N;Chambon, P
通讯作者: Chambon, P
DOI: 10.1084/jem.179.4.1145
发表时间: 1994-04-01
期刊: The Journal of experimental medicine
影响因子: --
作者:
Nakajima H;Sano H;Nishimura T;Yoshida S;Iwamoto I
通讯作者: Iwamoto I
DOI: 10.1084/jem.187.6.939
发表时间: 1998-03-16
期刊: The Journal of experimental medicine
影响因子: --
作者:
Kuperman D;Schofield B;Wills-Karp M;Grusby MJ
通讯作者: Grusby MJ